Asia and Global Semiconductor and Tech Research

Andrew Lu

Former Head of Asia ex-Japan Semiconductor and TFT-LCD/Touch Research at Barclays and Citi Bank, Former Head of Technology at 國金證券

Equity Bottom-Up

Taigen Biopharmaceuticals / Equity Bottom-Up

<h2>Summary</h2><ul>
<li>
<strong>What's new? </strong>Taigen and HEC Pharm announced a new joint venture.  HEC Pharm agrees Taigen to use its developed new drug Furaprevir (TG-2349) at RMB$335mn or NT$1.56bn investment value to take 49% of the new company.</li>
<li>
<strong>What is Furaprevir? </strong>On August 18, 2016, Taigen received a clinical trial authorization for Class 1.1 new drug from China Food and Drug Administration (CFDA) for Furaprevir. Furaprevir is an investigational HCV NS3 protease inhibitor discovered and developed by TaiGen for the…</li>
</ul>

Summary

What's new? Taigen and HEC Pharm announced a new joint venture.  HEC Pharm agrees Taigen to use its developed new drug Furaprevir (TG-2349) at RMB$335mn or NT$1.56bn investment value to take 49% of the new company.

What is Furaprevir? On August 18, 2016, Taigen received a clinical trial authorization for Class 1.1 new drug from China Food and Drug Administration (CFDA) for Furaprevir. Furaprevir is an investigational HCV NS3 protease inhibitor discovered and developed by TaiGen for the…


TaiGen Sold Its Furaprevir for 25x of Market Capital